Incyte INCY Business Segments — Sales and marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Incyte's business segments — sales and marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Incyte's business segments — sales and marketing?
- Incyte (INCY) reported business segments — sales and marketing of $285.75M in Q2 2026.
- How has Incyte's business segments — sales and marketing changed year-over-year?
- Incyte's business segments — sales and marketing increased by 11.5% year-over-year, from $256.31M to $285.75M.
- What is the long-term trend for Incyte's business segments — sales and marketing?
- Over 3 years (2022 to 2025), Incyte's business segments — sales and marketing has grown at a 12.4% compound annual growth rate (CAGR), from $770.14M to $1.09B.
- What does business segments — sales and marketing mean?
- This reflects the investment in commercializing the company's drug portfolio, including sales force compensation, advertising, promotional activities, and medical education. It is a key driver of revenue growth for marketed products.